...Lucia Masarova; Prithviraj Bose; Naveen Pemmaraju; Lingsha Zhou; Sherry Pierce; Zeev Estrov; Hagop Kantarjian; Srdan Verstovsek Introduction: Median duration of therapy with the first JAK1/2 inhibitor ruxolitinib (RUX) approved for patients with intermediate or high-risk myelofibrosis (MF) is about...

...(8;9)/PCM1-JAK2. Individuals with this abnormality have similar features, and JAK2 kinase inhibitor (ruxolitinib) is an effective treatment of the condition. The long-term remission results of ruxolitinib are varied. It is important to determine the response to ruxolitinib. Here, we describe a patient...

...Aaron T. Gerds; Jingbo Yu; Robyn M. Scherber; Dilan Paranagama; Jonathan K. Kish; Jay Visaria; Mukul Singhal; Srdan Verstovsek; Naveen Pemmaraju Ruxolitinib is an FDA-approved treatment of intermediate- and high-risk myelofibrosis. In the phase 3 COMFORT studies, ruxolitinib reduced spleen volume...

.... This prospective study was performed on consecutive patients presenting severe respiratory failure owing to COVID-19 or high-risk clinical condition associated with SARS-CoV-2, and who were treated with ruxolitinib for management of associated inflammation. Overall, 18 patients presenting SARS-CoV-2 viral-induced...

... rapid and sustained improvement in outcome with the use of ruxolitinib, a JAK/STAT pathway inhibitor. [email protected] 27 05 2020 13 07 2020 29 7 2020 © 2020 S. Karger AG, Basel 2020 Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part...

... of ruxolitinib in combination with post-transplant cyclophosphamide (PTCy). Patents and Methods: Twenty patients with primary or secondary myelofibrosis were prospectively enrolled. Reduced intensity conditioning was performed, followed by allogeneic stem cell transplantation from related ( n = 7) or unrelated...